每周顺铂联合放疗用于术后头颈癌(JCOG1008):一项多中心、非劣效性、II/III期随机对照试验
这项多中心开放标签II/III期随机试验纳入261例术后高危局部晚期头颈鳞癌患者,比较每周顺铂(40 mg/m2)与3周顺铂(100 mg/m2)化放疗。中位随访2.2年时,每周方案总生存非劣效于3周方案(HR 0.69,99.1% CI 0.374-1.273,非劣效性单侧P=0.0027),且3级以上中性粒细胞减少和感染更少。
要点
- 每周顺铂化放疗在术后高危局部晚期头颈鳞癌中总生存非劣效于3周顺铂。
- 每周组3级以上中性粒细胞减少49% vs 35%、感染12% vs 7%,均低于3周组。
- 每周组治疗相关死亡2例(1.6%),3周组无治疗相关死亡。
核心结论
- 每周顺铂化放疗对术后高危局部晚期头颈鳞癌患者的总生存非劣效于3周顺铂化放疗。
- 作者认为每周顺铂化放疗可作为这些患者的一种可能治疗选择。
研究设计与样本
- 多中心开放标签II/III期随机对照试验,纳入术后高危局部晚期头颈鳞癌患者261例。
- 患者随机接受3周顺铂(100 mg/m2)化放疗132例或每周顺铂(40 mg/m2)化放疗129例。
- II期主要终点为治疗完成比例,III期主要终点为总生存,非劣效性界值设为风险比1.32。
主要发现
- 2012年10月至2018年12月共入组261例,中位随访2.2年(四分位距1.19-3.56)。
- 每周顺铂组总生存非劣效于3周顺铂组,风险比0.69(99.1% CI 0.374-1.273,低于1.32),非劣效性单侧P=0.0027(小于0.0043)。
- 3级及以上中性粒细胞减少3周组49% vs 每周组35%,感染3周组12% vs 每周组7%,每周组均更低。
- 肾功能损害和听力损害在每周组也更少。
- 治疗相关死亡3周组0例,每周组2例(1.6%)。
关键数值与推荐
- 非劣效性界值风险比1.32。
- 总生存风险比0.69(99.1% CI 0.374-1.273),非劣效性单侧P=0.0027。
- 3级及以上中性粒细胞减少:3周组49% vs 每周组35%。
- 3级及以上感染:3周组12% vs 每周组7%。
- 治疗相关死亡:3周组0例,每周组2例(1.6%)。
临床怎么用
- 作者认为每周顺铂化放疗可作为术后高危局部晚期头颈鳞癌患者的一种可能治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The standard treatment for postoperative high-risk locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) is chemoradiotherapy with 3-weekly cisplatin (100 mg/m2). However, whether chemoradiotherapy with weekly cisplatin (40 mg/m2) yields comparable efficacy with 3-weekly cisplatin in postoperative high-risk LA-SCCHN is unknown. PATIENTS AND METHODS: In this multi-institutional open-label phase II/III trial, patients with postoperative high-risk LA-SCCHN were randomly assigned to receive either chemoradiotherapy with 3-weekly cisplatin (100 mg/m2) or with weekly cisplatin (40 mg/m2) to confirm the noninferiority of weekly cisplatin. The primary end point of phase II was the proportion of treatment completion, and that of phase III was overall survival. A noninferiority margin of hazard ratio was set at 1.32. RESULTS: Between October 2012 and December 2018, a total of 261 patients were enrolled (3-weekly cisplatin, 132 patients; weekly cisplatin, 129 patients). At the planned third interim analysis in the phase III part, after a median follow-up of 2.2 (interquartile range 1.19-3.56) years, chemoradiotherapy with weekly cisplatin was noninferior to 3-weekly cisplatin in terms of overall survival, with a hazard ratio of 0.69 (99.1% CI, 0.374 to 1.273 [< 1.32], one-sided P for noninferiority = .0027 < .0043). Grade 3 or more neutropenia and infection were less frequent in the weekly arm (3-weekly v weekly, 49% v 35% and 12% v 7%, respectively), as were renal impairment and hearing impairment. No treatment-related death was reported in the 3-weekly arm, and two (1.6%) in the weekly arm. CONCLUSION: Chemoradiotherapy with weekly cisplatin is noninferior to 3-weekly cisplatin for patients with postoperative high-risk LA-SCCHN. These findings suggest that chemoradiotherapy with weekly cisplatin can be a possible treatment option for these patients.
引用
- Kiyota N, Tahara M, Mizusawa J, et al. Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial. J Clin Oncol. 2022. PMID: 35230884. doi:10.1200/JCO.21.01293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。